Effect of substrate and fibrin polymerization inhibitor on determination of plasma thrombin generation in vitro

Thrombosis Research

Volumn 119, Issue 6, 2007, Pages 667-677

  Lau, A ^a   Berry, L R ^b   Mitchell, L G ^c   Chan, A K C ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anticoagulant; Fibrin; Method; Plasma; Thrombin generation

Indexed keywords

4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; ALPHA 2 MACROGLOBULIN; ANCROD; ANTITHROMBIN; CALCIUM CHLORIDE; EDETIC ACID; FIBRIN POLYMERIZATION INHIBITOR; HIRUDIN; PROTEIN INHIBITOR; THROMBOPLASTIN; TROMETAMOL; UNCLASSIFIED DRUG;

ABSORPTION; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; FIBRIN POLYMERIZATION; HUMAN; HUMAN TISSUE; PLASMA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TEMPERATURE; THROMBIN TIME;

ADULT; ANTICOAGULANTS; ANTITHROMBINS; BIOPOLYMERS; BLOOD CHEMICAL ANALYSIS; CHROMOGENIC COMPOUNDS; FIBRIN; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POLYSACCHARIDES; THROMBIN; TIME FACTORS;

EID: 33947330144     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.05.008     Document Type: Article

References (33)

1. ten Cate H., Bauer K.A., Levi M., Edgington T.S., Sublett R.D., Barzegar S., et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 92 (1993) 1207-1212
2. Eilertsen K.E., and Osterud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 15 (2004) 521-538
3. Ofosu F.A., Sie P., Modi G.J., Fernandez F., Buchanan M.R., Blajchman M.A., et al. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 243 (1987) 579-588
4. Ofosu F.A., Liu L., and Feedman J. Control mechanisms in thrombin generation. Semin Thromb Haemost 22 (1996) 303-308
5. Naito K., and Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII: factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 266 (1991) 7353-7358
6. Hemker H.C., and Beguin S. Phenotyping the clotting system. Thromb Haemost 84 (2000) 747-751
7. Hemker H.C., Wielders S., Kessels H., and Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 70 (1993) 617-624
8. Biggs R., and Macfarlane R.G. Human blood coagulation and its disorders (1957), Blackwell Scientific Publications, Oxford
9. Massicotte M.P., Leaker M., Marzinotto V., Adams M., Freedom R., Williams W., et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost 80 (1998) 570-574
10. Andrew M., Vegh P., Johnston M., Bowker J., Ofosu F., and Mitchell L. Maturation of the hemostatic system during childhood. Blood 80 (1992) 1998-2005
11. Andrew M., Paes B., Milner R., Johnston M., Mitchell L., Tollefsen D.M., et al. Development of the human coagulation system in the full-term infant. Blood 70 (1987) 165-172
12. Andrew M., Paes B., Milner R., Johnston M., Mitchell L., Tollefsen D.M., et al. Development of the human coagulation system in the healthy premature infant. Blood 72 (1988) 1651-1657
13. Kumar R., Beguin S., and Hemker H.C. The influence of fibrinogen and fibrin on thrombin generation-evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 72 (1994) 713-721
14. Hemker H.C., Giesen P., Al Dieri R., Regnault V., de Smed E., Wagenvoord R., et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Thromb Haemost 32 (2002) 249-253
15. Hemker H.C., and Beguin S. Endogenous thrombin potential. In: Jespersen J., Bettina R.M., and Haverkate F. (Eds). Laboratory techniques in thrombosis-a manual (1999), Kluwer Academic Publishers, Boston, MA 63-78
16. Bostrom S.L., Hansson G.F., Sarich T.C., and Wolzt M. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enxoparin and r-hirudin on ex vivo thrombin generation in human plasma. Thromb Res 113 (2004) 85-91
17. Hemker H.C., and Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 74 (1995) 134-138
18. Schmidt B., Ofosu F.A., Mitchell L., Brooker L.A., and Andrew M. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 25 (1989) 405-408
19. Bovill E.G., Tracy R.P., Hayes T.E., Jenny R.J., Bhushan F.H., and Mann K.G. Evidence that meizothrombin is an intermediate product in the clotting of whole blood. Arterioscler Thromb Vasc Biol 15 (1995) 754-758
20. Han J.H., Cote H.C., and Tollefsen D.M. Inhibition of meizothrombin and meizothrombin(desF1) by heparin cofactor II. J Biol Chem 272 (1997) 28660-28665
21. Wilner G.D., Danitz M.P., Mudd M.S., Hsieh K.H., and Fenton J.W.I.I. Selective immobilization of alpha-thrombin by surface-bound fibrin. J Lab Clin Med 97 (1981) 403-401
22. Hemker H.C., Giesen P., Al Dieri R., Regnault V., de Smedt E., Wagenvoord R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33 (2003) 4-15
23. Fredenburgh J., Stafford A.R., Pospisil C.H., and Weitz J.I. Modes and consequences of thrombin's interaction with fibrin. Biophys Chem 112 (2004) 277-284
24. Bick R.L., Frenkel E.P., Walenga J., Fareed J., and Hoppensteadt D.A. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin North Am 19 (2005) 1-51
25. Depasse F., Gerotziafas G.T., Busson J., Van Dreden P., and Samama M.M. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J Thromb Haemost 2 (2004) 346-348
26. Gerotziafas G.T., Depasse F., Chakroun T., Van Dreden P., Samama M.M., and Elalamy I. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagul Fibrinolysis 15 (2004) 149-156
27. Furlan M., Rupp C., Beck E.A., and Svendsen L. Effect of calcium and synthetic peptides on fibrin polymerization. Thromb Haemost 47 (1982) 118-121
28. Francis C.W., Markham Jr. R.E., Barlow G.H., Florack T.M., Dobrzynski D.M., and Marder V.J. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 102 (1983) 220-230
29. Greenberg C.S., and Miraglia C.C. The effect of fibrin polymers on thrombin-catalyzed plasma factor XIIIa formation. Blood 66 (1985) 466-469
30. Kam P.C., Kaur N., and Thong C.L. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia 60 (2005) 565-574
31. Hemker H.C., Al Dieri R., and Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 11 (2004) 170-175
32. Hemker H.C., Willems G.M., and Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 56 (1986) 9-17
33. Weitz J.I. A novel approach to thrombin inhibition. Thromb Res 109 (2003) S17-S22